An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma
The goal of this clinical research study is to learn if everolimus can help to control Hodgkin lymphoma. The safety of this drug will also be studied.
Treatment Location: N/A
Primary objectives To determine the objective response rate to therapy with 10 mg everolimus in patients with refractory/relapsed classical Hodgkin lymphoma (HL) (determined by Positron Emission Tomography PET and computer tomography CT scans). Secondary objectives To assess the time to response To assess the duration of response To determine the disease control rate (complete response (CR), partial response (PR), and stable disease (SD)) To evaluate progression-free survival and overall survival To determine the safety and tolerability of 10 mg qd everolimus monotherapy
IRB Review and Approval Date: 08/30/2010
Recruitment Status: Closed
Projected Accrual: N/A